Latest & greatest articles for losartan

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on losartan or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on losartan and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for losartan

21. Losartan/ hydrochlorothiazide (Cozaar-Comp 100/25)

Losartan/ hydrochlorothiazide (Cozaar-Comp 100/25) Scottish Medicines Consortium Secretariat - Delta House 50 West Nile Street Glasgow G1 2NP Telephone 0141 225 6989 E-mail: Rosie.Murray@nhshealthquality.org Chairman Professor David Webb losartan 100mg/ hydrochlorothiazide 25mg tablets (Cozaar-Comp 100/25) (No. 296/06) Merck, Sharp & Dohme Ltd Product Update 7 July 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises the NHS Boards and Area (...) Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission Losartan 100mg/hydrochlorothiazide 25mg tablet (Cozaar-Comp 100/25 Ò ) is accepted for use within NHS Scotland for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled on hydrochlorothiazide or losartan monotherapy. No increased costs are associated with this product compared with losartan (Cozaar

Scottish Medicines Consortium2006

22. Effects of losartan-based therapy on the incidence of end-stage renal disease and associated costs in type 2 diabetes mellitus: a retrospective cost-effectiveness analysis in the United Kingdom

Effects of losartan-based therapy on the incidence of end-stage renal disease and associated costs in type 2 diabetes mellitus: a retrospective cost-effectiveness analysis in the United Kingdom Effects of losartan-based therapy on the incidence of end-stage renal disease and associated costs in type 2 diabetes mellitus: a retrospective cost-effectiveness analysis in the United Kingdom Effects of losartan-based therapy on the incidence of end-stage renal disease and associated costs (...) in type 2 diabetes mellitus: a retrospective cost-effectiveness analysis in the United Kingdom Vora J, Carides G, Robinson P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of losartan (50 - 100 mg once daily) for the prevention

NHS Economic Evaluation Database.2005

23. Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial

Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial Jonsson B, Carides G W, Burke T A, Dasbach E J, Lindholm L H, Dahlof B Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of the antihypertensive drug losartan for the prevention of stroke. Type of intervention Prevention. Economic study type Cost-utility analysis. Study population The study population comprised patients aged between 55 and 80 years who had

NHS Economic Evaluation Database.2005

24. Losartan reduces the costs associated with nephropathy and end-stage renal disease from Type 2 diabetes: economic evaluation of the RENAAL study from a Canadian perspective

Losartan reduces the costs associated with nephropathy and end-stage renal disease from Type 2 diabetes: economic evaluation of the RENAAL study from a Canadian perspective Losartan reduces the costs associated with nephropathy and end-stage renal disease from Type 2 diabetes: economic evaluation of the RENAAL study from a Canadian perspective Losartan reduces the costs associated with nephropathy and end-stage renal disease from Type 2 diabetes: economic evaluation of the RENAAL study from (...) a Canadian perspective Burgess E D, Carides G W, Gerth W C, Marentette M A, Chabot I Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of losartan (50 to 100 mg once daily) taken in addition to conventional antihypertensive

NHS Economic Evaluation Database.2004

25. Cost-effectiveness of losartan versus atenolol in treating hypertension: an analysis of the LIFE study from a Swiss perspective

Cost-effectiveness of losartan versus atenolol in treating hypertension: an analysis of the LIFE study from a Swiss perspective Cost-effectiveness of losartan versus atenolol in treating hypertension: an analysis of the LIFE study from a Swiss perspective Cost-effectiveness of losartan versus atenolol in treating hypertension: an analysis of the LIFE study from a Swiss perspective Szucs T D, Burnier M, Erne P Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared the use of an angiotensin II receptor blocker (losartan) with the use of a beta-blocker (atenolol) in patients with essential hypertension. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study

NHS Economic Evaluation Database.2004

28. Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study.

Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, a major reduction of all-cause mortality--especially cardiovascular mortality--in patients with diabetes with left ventricular hypertrophy was reported for treatment with losartan. We postulated post hoc that losartan might have a better effect on sudden cardiac death than atenolol, and we aimed to test this hypothesis (...) . 44 patients with diabetes died of sudden cardiac death; significantly fewer deaths arose in the losartan group (14) than in the atenolol group (30; p=0.027). In the losartan group, five (6%) of 86 patients with diabetes and atrial fibrillation during the trial died of sudden cardiac death compared with nine (2%) of 500 in those without atrial fibrillation. The respective figures for the atenolol group were 14 (13%) of 105 and 16 (3%) of 504. Our results suggest losartan affords better protection

Lancet2003

29. Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation

Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation Herman W H, Shahinfar S, Carides G W, Dasbach E J, Gerth W C, Alexander C M, Cook J R, Keane W F, Brenner B M Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of losartan combined with conventional antihypertensive therapy (CAHT). CAHT included diuretics, calcium-channel antagonists, alpha- or beta-blockers, centrally acting agents, or some combination of these, but excluded

NHS Economic Evaluation Database.2003

30. Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union

Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union Gerth W C, Remuzzi G, Viberti G, Hannedouche T, Martinez-Castelao A, Shahinfar S, Carides G W, Brenner B Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The angiotensin-II-receptor antagonist losartan and standard antihypertensive therapy were compared to treatment with placebo and standard antihypertensive therapy. The dose of losartan was altered to achieve a target

NHS Economic Evaluation Database.2002

31. The potential economic consequences of cognitive improvement with losartan

The potential economic consequences of cognitive improvement with losartan The potential economic consequences of cognitive improvement with losartan The potential economic consequences of cognitive improvement with losartan Jonsson L, Gerth W, Fastbom J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology The use of losartan (50 mg once daily), an angiotensin-converting enzyme inhibitor, to improve cognitive function in hypertensive patients. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised elderly mild-to-moderate hypertensive patients (diastolic blood pressure 90 to 114 mmHg), with no diagnosis of dementia at baseline and with a Mini-Mental State

NHS Economic Evaluation Database.2002

32. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. 11937178 2002 04 08 2002 04 24 2015 06 16 0140-6736 359 9311 2002 Mar 23 Lancet (London, England) Lancet Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. 995-1003 Blood pressure reduction achieved with beta-blockers and diuretics (...) with essential hypertension (sitting blood pressure 160-200/95-115 mm Hg) and LVH ascertained by electrocardiography (ECG). We assigned participants once daily losartan-based or atenolol-based antihypertensive treatment for at least 4 years and until 1040 patients had a primary cardiovascular event (death, myocardial infarction, or stroke). We used Cox regression analysis to compare regimens. Blood pressure fell by 30.2/16.6 (SD 18.5/10.1) and 29.1/16.8 mm Hg (19.2/10.1) in the losartan and atenolol groups

Lancet2002

33. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. 11937179 2002 04 08 2002 04 24 2015 06 16 0140-6736 359 9311 2002 Mar 23 Lancet (London, England) Lancet Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. 1004-10 The most suitable (...) antihypertensive drug to reduce the risk of cardiovascular disease in patients with hypertension and diabetes is unclear. In prespecified analyses, we compared the effects of losartan and atenolol on cardiovascular morbidity and mortality in diabetic patients. As part of the LIFE study, in a double-masked, randomised, parallel-group trial, we assigned a group of 1195 patients with diabetes, hypertension, and signs of left-ventricular hypertrophy (LVH) on electrocardiograms losartan-based or atenolol-based

Lancet2002

34. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.

Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. 12243636 2002 09 23 2002 10 04 2016 10 17 0098-7484 288 12 2002 Sep 25 JAMA JAMA Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy (...) . 1491-8 Drug intervention in placebo-controlled trials has been beneficial in isolated systolic hypertension. To test the hypothesis that losartan improves outcome better than atenolol in patients with isolated systolic hypertension and electrocardiographically documented left ventricular hypertrophy (ECG-LVH). Double-blind, randomized, parallel-group study conducted in 1995-2001. A total of 1326 men and women aged 55 through 80 years (mean, 70 years) with systolic blood pressure of 160 to 200 mm Hg

JAMA2002

35. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan.

Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. 12241832 2002 09 20 2002 10 02 2015 06 16 0140-6736 360 9335 2002 Sep 07 Lancet (London, England) Lancet Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial (...) in Myocardial Infarction with Angiotensin II Antagonist Losartan. 752-60 ACE inhibitors attenuate the detrimental effects of angiotensin II, and improve survival and reduce morbidity in patients with acute myocardial infarction and evidence of heart failure or left-ventricular dysfunction. Selective antagonism of the angiotensin type 1 receptor represents an alternative approach to inhibition of the renin-angiotensin system. We did a multicentre, randomised trial to test the hypothesis that the angiotensin II

Lancet2002

36. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. 11565518 2001 09 07 2001 09 27 2016 08 03 0028-4793 345 12 2001 Sep 20 The New England journal of medicine N. Engl. J. Med. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. 861-9 Diabetic nephropathy is the leading cause of end-stage renal disease. Interruption of the renin-angiotensin system slows the progression of renal disease (...) in patients with type 1 diabetes, but similar data are not available for patients with type 2, the most common form of diabetes. We assessed the role of the angiotensin-II-receptor antagonist losartan in patients with type 2 diabetes and nephropathy. A total of 1513 patients were enrolled in this randomized, double-blind study comparing losartan (50 to 100 mg once daily) with placebo, both taken in addition to conventional antihypertensive treatment (calcium-channel antagonists, diuretics, alpha-blockers

NEJM2001

37. Losartan: a review of its use, with special focus on elderly patients

Losartan: a review of its use, with special focus on elderly patients Losartan: a review of its use, with special focus on elderly patients Losartan: a review of its use, with special focus on elderly patients Simpson K L, McClellan K J Authors' objectives To assess the efficacy of losartan for the treatment of hypertension and heart failure, with particular reference to the elderly. Searching AdisBase, MEDLINE and EMBASE were searched from 1966 to 10th January 2000, for medical literature (...) published in any language. The search terms were: for AdisBase terms, 'losartan' and 'congestive heart failure' or 'hypertension' or elderly'; for MEDLINE, 'losartan' and 'heart-failure-congestive' or 'hypertension' or 'aged'. The reference lists of papers were examined for additional material, and drug companies were contacted for unpublished studies. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) were included. For hypertension, all the studies

DARE.2000

38. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. 10821361 2000 06 07 2000 06 07 2015 06 16 0140-6736 355 9215 2000 May 06 Lancet (London, England) Lancet Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. 1582-7 The ELITE study showed an association between (...) the angiotensin II antagonist losartan and an unexpected survival benefit in elderly heart-failure patients, compared with captopril, an angiotensin-converting-enzyme (ACE) inhibitor. We did the ELITE II Losartan Heart Failure Survival Study to confirm whether losartan is superior to captopril in improving survival and is better tolerated. We undertook a double-blind, randomised, controlled trial of 3,152 patients aged 60 years or older with New York Heart Association class II-IV heart failure and ejection

Lancet2000

39. The cost-effectiveness of losartan versus captopril in patients with symptomatic heart failure

The cost-effectiveness of losartan versus captopril in patients with symptomatic heart failure The cost-effectiveness of losartan versus captopril in patients with symptomatic heart failure The cost-effectiveness of losartan versus captopril in patients with symptomatic heart failure Dasbach E J, Rich M W, Segal R, Gerth W C, Carides G W, Cook J R, Murray J F, Snavely D B, Pitt B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) data were used. Source of effectiveness data Effectiveness data were derived from a single study. Link between effectiveness and cost data Cost data were collected prospectively using the same patient sample as in the clinical analysis. Study sample 352 patients were randomised to receive losartan with 370 patients receiving captopril. The population sample used in the trial was appropriate, as symptomatic heart failure is increasing most significantly in more elderly populations. Power

NHS Economic Evaluation Database.1999

40. Effects of losartan and captopril on QT dispersion in elderly patients with heart failure. ELITE study group.

Effects of losartan and captopril on QT dispersion in elderly patients with heart failure. ELITE study group. 10437875 1999 08 12 1999 08 12 2015 06 16 0140-6736 354 9176 1999 Jul 31 Lancet (London, England) Lancet Effects of losartan and captopril on QT dispersion in elderly patients with heart failure. ELITE study group. 395-6 Differences in QT dispersion (a predictor for sudden death) were observed in a subgroup of patients in the ELITE heart failure study of losartan compared with captopril (...) , and may explain improved survival with losartan. Brooksby P P Robinson P J PJ Segal R R Klinger G G Pitt B B Cowley A J AJ eng Clinical Trial Comparative Study Letter Randomized Controlled Trial England Lancet 2985213R 0140-6736 0 Angiotensin-Converting Enzyme Inhibitors 0 Anti-Arrhythmia Agents 0 Cardiotonic Agents 9G64RSX1XD Captopril JMS50MPO89 Losartan AIM IM Aged Angiotensin-Converting Enzyme Inhibitors adverse effects therapeutic use Anti-Arrhythmia Agents adverse effects therapeutic use

Lancet1999